Subscribe

Subscribe to CONQUER: the patient voice™ magazine

Receive timely cancer news & updates, patient stories, and more.

First Name *
Last Name *
Need multiple copies? Click here
 
 
Subscribe

Subscribe to CONQUER: the patient voice™ magazine

Receive timely cancer news & updates, patient stories, and more.

First Name *
Last Name *
Need multiple copies? Click here
 

Newsworthy

Newsworthy
As part of its mission to provide help and hope to anyone affected by a cancer diagnosis, CancerCare® is offering direct financial assistance to cancer patients residing in the United States, including Puerto Rico and the U.S. Virgin Islands, who have been impacted by Hurricanes Harvey, Irma, Jose or Maria.
FDA NewsNewsworthy
On April 17, 2017, the FDA approved the PD-L1 inhibitor Tecentriq (atezolizumab; from Genentech) for use as first-line treatment for patients with locally advanced or metastatic urothelial carcinoma who cannot use cisplatin chemotherapy.
FDA NewsNewsworthy
This section provides a brief overview of new medications approved by the FDA between the end of December 2016 and mid-March 2017.
FDA NewsNewsworthy
In March 2017, the FDA approved Kisqali (ribociclib), in combination with an aromatase inhibitor, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Page 1 of 3
Results 1 - 10 of 21